Current Issue

20% by 2020
David B. Nash, MD, MBA
April 2018 Vol 11, No 2 - Editorial
Read More
Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System
Raghu Durvasula, MD, MHA, Janet Kelly, PharmD, Anneliese Schleyer, MD, MHA, Bradley D. Anawalt, MD, Shabir Somani, MS, MBA, RPh, FASHP, Timothy H. Dellit, MD
April 2018 Vol 11, No 2 - Business
Stakeholder Perspective
Pharmacy & Therapeutics Committees’ New Challenge: Stewardship for Specialty Drugs
by Byron C. Scott, MD, MBA
Read More
New Rivals: Integrating Health Benefits to Provide Comprehensive Patient Care
Gary Branning, MBA, Martha Vater
April 2018 Vol 11, No 2 - Industry Trends
Read More
Effects of Educational Messaging on Urgent and Emergent Care–Seeking Behaviors Among Publicly Insured Populations
Jesse Cambon, MEng, Tristan Cordier, MS, Elizabeth L. Munnich, PhD, MPP, Andrew Renda, MD, Bobby Kapur, MD, MPH, Shkelzen Hoxhaj, MD, MPH, MBA, Meredith Williams, MD, MBA
April 2018 Vol 11, No 2 - Business, Original Research
Stakeholder Perspective
Opportunities to Improve Urgent and Emergent Care Utilization
by Cody Olsen, PharmD, BCPS
Read More
Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study
Todd Williamson, PhD, MSc, Wendy Y. Cheng, MPhil, MPH, Nora McCormick, MSc, Francis Vekeman, MA
April 2018 Vol 11, No 2 - Clinical, Original Research
Stakeholder Perspective
There’s Room for Improvement in Rosacea Treatment
by Gary M. Owens, MD
Read More

Conference Correspondent

Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent - ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent - ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent - ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Conference Correspondent - ACR 2017, Conference Correspondent

Most Popular Articles

Healthcare Trends for 2018
F. Randy Vogenberg, RPh, PhD, John Santilli, MBA
February 2018 Vol 11, No 1 - Industry Trends
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States
Eric M. Maiese, MHS, PhD, Kristin A. Evans, PhD, Bong-Chul Chu, PhD, Debra E. Irwin, MSPH, PhD
February 2018 Vol 11, No 1 - Business, Original Research
Predictors of Transitioning to Incident Chronic Opioid Therapy Among Working-Age Adults in the United States
J. Douglas Thornton, PharmD, PhD, Nilanjana Dwibedi, PhD, Virginia Scott, PhD, Charles D. Ponte, PharmD, Douglas Ziedonis, MD, Nethra Sambamoorthi, PhD, Usha Sambamoorthi, PhD
February 2018 Vol 11, No 1 - Clinical
Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines
Gabriela Dieguez, FSA, MAAA, Christine Ferro, Maushumi Mavinkurve, MPH, Yuri Sanchez Gonzalez, PhD, Bruce Pyenson, FSA, MAAA
February 2018 Vol 11, No 1 - Clinical
FDA Approvals in 2017 Represent a 21-Year High
Gary M. Owens, MD
March 2018, Vol 11, Ninth Annual Payers' Guide - FDA Approvals, News & Updates

Web Exclusives

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer
HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan.
Read More

Select Drug Updates

Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation
View All Updates

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?


  • Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME